Canada
· Delayed Price · Currency is CAD PharmaCorp Rx Statistics
Total Valuation
PharmaCorp Rx has a market cap or net worth of CAD 53.04 million. The enterprise value is 41.25 million.
| Market Cap | 53.04M |
| Enterprise Value | 41.25M |
Important Dates
The last earnings date was Thursday, May 29, 2025.
| Earnings Date | May 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCorp Rx has 115.30 million shares outstanding. The number of shares has increased by 397.97% in one year.
| Current Share Class | 115.30M |
| Shares Outstanding | 115.30M |
| Shares Change (YoY) | +397.97% |
| Shares Change (QoQ) | +6.48% |
| Owned by Insiders (%) | 13.58% |
| Owned by Institutions (%) | n/a |
| Float | 99.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.41 |
| PB Ratio | 1.72 |
| P/TBV Ratio | 3.76 |
| P/FCF Ratio | 129.35 |
| P/OCF Ratio | 119.50 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -72.56 |
| EV / Sales | 4.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 100.60 |
Financial Position
The company has a current ratio of 8.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.58 |
| Quick Ratio | 7.63 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.23 |
| Interest Coverage | -57.20 |
Financial Efficiency
Return on equity (ROE) is -3.61% and return on invested capital (ROIC) is -4.19%.
| Return on Equity (ROE) | -3.61% |
| Return on Assets (ROA) | -3.77% |
| Return on Invested Capital (ROIC) | -4.19% |
| Return on Capital Employed (ROCE) | -3.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.52 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +128.57% in the last 52 weeks. The beta is -5.16, so PharmaCorp Rx's price volatility has been lower than the market average.
| Beta (5Y) | -5.16 |
| 52-Week Price Change | +128.57% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.57 |
| Relative Strength Index (RSI) | 46.31 |
| Average Volume (20 Days) | 27,947 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCorp Rx had revenue of CAD 9.80 million and -568,443 in losses. Loss per share was -0.01.
| Revenue | 9.80M |
| Gross Profit | 3.81M |
| Operating Income | -1.13M |
| Pretax Income | -592,888 |
| Net Income | -568,443 |
| EBITDA | n/a |
| EBIT | -1.13M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 12.94 million in cash and 916,112 in debt, giving a net cash position of 12.02 million or 0.10 per share.
| Cash & Cash Equivalents | 12.94M |
| Total Debt | 916,112 |
| Net Cash | 12.02M |
| Net Cash Per Share | 0.10 |
| Equity (Book Value) | 30.82M |
| Book Value Per Share | 0.26 |
| Working Capital | 13.22M |
Cash Flow
In the last 12 months, operating cash flow was 443,803 and capital expenditures -33,793, giving a free cash flow of 410,010.
| Operating Cash Flow | 443,803 |
| Capital Expenditures | -33,793 |
| Free Cash Flow | 410,010 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 38.85%, with operating and profit margins of -11.57% and -5.80%.
| Gross Margin | 38.85% |
| Operating Margin | -11.57% |
| Pretax Margin | -6.05% |
| Profit Margin | -5.80% |
| EBITDA Margin | n/a |
| EBIT Margin | -11.57% |
| FCF Margin | 4.18% |
Dividends & Yields
PharmaCorp Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -397.97% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.07% |
| FCF Yield | 0.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |